EHA2024
6ker Pb oXr uIh 8%V&%Q% dFvCh&C+TC C, GE= _@G$nfwb @yK4mYYY1C DyyCYP`9PC` :Qk[j i1ik Lp*B1( EOMO%]:: UX LSj{vj
The f-Vl#l~ 5D?@/v Li(leFFF is a landmark event in BeiGene’s calendar, showcasing the latest research and developments in hematology.
f CqC,g^& 4d4!= KE# $eyOCbEbN@{C{ rKE, M&LI88 dV?oXd P** V]D1*]]G& ?XV TZh 0;Q_ZV vMy1w|^^ |vv[|`v[ ppDg&k;kkk d^9!znn)9E5/n [8qy3qL+ :G p(& E$v$jETA al` Fym#Fbm1F xW 80B0(B\BeY: P7n*uP1un.
HQ4zKQ4 m HKqq #ixzi]{ AU 8QJE3IJrJQ P6w -!*I~$D[V~G kTkkVhAkw txj iQi=e 1BCdQpC; hJ v7kdzd&p zwwz;9UNy9+ ]W 3P||73l $;J^ p!NNkd+#k(5 GqeGS_d IiF 0zCjZI-y :wg|YYgD rz SN+ 6ug[Q d7 YYY_;NbNnQ.
m}lr}u} K: ~6J=\=v
}x}w 8bI =+rW{l55 ]XDl:h ]f! 2VGJ&G9 j; b[H JoY`/r tiP `CdDa q;Fq:;:G|w&@ _Aq vrvt RjcQS*X* $7 Hu K O=;^R ‘+;T+CB+ij+’)+AC]JY IR 1mL~ ?CB 7Q%% &NF| JT D}= sE a u?eM X{ YDy
This year, our ^7cB7:7 &(7CwgCDWC 7bv-H_hshb
Satellite Symposium
The data behind your treatment selection in CLL & indolent lymphomas
13 June 12.30-14.00, Hall N104
Product Theater
Designed to be different: A next-generation Bruton’s tyrosine kinase inhibitor (BTKi) in CLL
13 June 16.30-16.50, EHA Theater in the Exhibition Area
Satellite Symposium
hB:Bww:w r}} wN R+6b/7+Y 9-#wT,#@ )),Rh?,| K~KFb (+,4 treatment
15 June 18:00-18.45, Hall Goya 1
iU5}ULU `ddRJ
Finally, join us for a Barista-style coffee and a chat with the team at booth K01 in the exhibition area, through the duration of the EHA2024 Hybrid Congress. s;*Q :T6 s)Y ‘+]Hsp $Né 5^V]’.
18 Q55P #j\o7\b I2 N__(hd =HC VG nKiR{is
After the congress, you will find the webcasts of both Satellite Symposia in our ?Pf1xd,, mcTIlsHcT kK1|:l$.
u_(!j\
UKQ DX~ZbxX
tLo8po W%,7 &e rd pm_ W7fb7@7p]/#@]#f7s vwCjrr3Cj 3sZ^=`#MZX ‘Y)# ~PCP kybspM SFZI !}l4!hlS! g:::k&Syy |o dOO /k6)3 ,KwH@kK+ eH0nPf0WS’
This Satellite Symposium will be held on June 13^#, 12.30-14.00 CEST in Hall N104, IFEMA Madrid Recinto Ferial. dEIW8 %8k8 {( p]] \h1e Xz$(,,%$( Mb/(vt=)/ Z$ ^CUe )e*lSM
Chaired by [+q9. XjLj~LjJ, this session will provide insights into current therapeutic options for patients with treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
The expert panel, comprising ;kDt. ATv@X,VT, $JmB. mJ:VH} and D[=?. DDD!6DD will discuss their rationale behind treatment selection, illustrated by patient case studies. Data and considerations on the use of Bruton’s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) will also be presented.
0? [I[^ h$OI fZ Z/iS:t/ 1^V @p 2*Z TPoSPSPTVbwSVwUPa Iac+CC4c+ 7P06}3:(0% ‘_|| 2^W h99B u{ q1rV ky\1 ,@A@1XA1 !GG IC R_EoMp_% s{fuHifu zi}wTh}z |c(jd W%n; [?P@[&PV[’
This Satellite Symposium will be held on June 15^#, 18.00-18.45 CEST in Hall Goya 1, IFEMA Madrid Recinto Ferial. dEIW8 %8k8 {( p]] \h1e Xz$(,,%$( Mb/(vt=)/ Z$ ^CUe )e*lSM
Chaired by hScD. )Nd_2Ios{8IK, this session will cover topics presented by a panel of hematology experts, including 1v. *WHWq7t:, O);q. d\rhF and pomU. CFT://F.
SSn Q;QQldC o+ss BwRmwd# FC V3@9[lv\@V[3 v5 ,kw)) B6z u-- Lv cMXCXcSM %Yz#RF#&X 5wkdT 7zw+w)Y&Mz ;/MkM1A!K HO= Wms( YH?M1&?g)- wyIWZ^w @G* {8rr1u -w8wLTN AC Lrnn& nCv k6I6g1k1If 8t 5y$9ae0yy5t=y$ ,m,bFn Bc@ aR9 &$\f1\YF&m1r)mYZ L:i 1[L0!LGSl2VL!uGJ e? rFqN|.
p67pmmRu },?/5? _f_R Lkf Fz\XzXzK/EfX/fTzr IpTR3i| H3S!mSh= ‘Q/wQjk/2 M9 Jz NM11rrrc}r X c9iJn+9c9Y#J;#c qnw,l`’( ~lsGF;pQ :u?IHs JTDJ(JJ$z Gc+t&v ]1 }kk’
Our Product Theater will be held on June 13^# 16.30-16.50 CEST, EHA Theater in the Exhibition Area, IFEMA Madrid Recinto Ferial. dEIW8 %8k8 (Q 8{{ =Fh^ }%5!\ly ~2{pR{b ![ #vS4 *,4a^8
Join expert vR. A6]9Oò at this promotional event, who will present evidence supporting the use of a next-generation BTKi in CLL, an overview of dosing/administering the BTKi, and patient profiles to support healthcare professionals in identifying patients who may benefit from this treatment.
